TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
-6.78%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.35B
AUM Growth
+$2.35B
(-9.7%)
Cap. Flow
-$36.9M
Cap. Flow
% of AUM
-1.57%
Top 10 Holdings %
Top 10 Hldgs %
44.73%
Holding
156
New
14
Increased
27
Reduced
18
Closed
11
Top Buys
| 1 |
Biogen
BIIB
|
$15.7M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$12.3M |
| 3 |
Johnson & Johnson
JNJ
|
$12.2M |
| 4 |
SPDR S&P Biotech ETF
XBI
|
$10.6M |
| 5 |
CCP
Care Capital Properties, Inc.
CCP
|
$8.63M |
Top Sells
| 1 |
Alkermes
ALKS
|
$27.4M |
| 2 |
Agilent Technologies
A
|
$21.7M |
| 3 |
CPHD
Cepheid Inc
CPHD
|
$17.6M |
| 4 |
Eli Lilly
LLY
|
$16.2M |
| 5 |
UnitedHealth
UNH
|
$13.6M |
Sector Composition
| 1 | Healthcare | 90.58% |
| 2 | Real Estate | 3.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Gilead Sciences
GILD
$140B
| $181M | 7.72% | 2,530,131 -130,000 | -5% | -$9.31M |
|
|
CELG
2
DELISTED
Celgene Corp
CELG
| $163M | 6.95% | 1,409,889 -74,200 | -5% | -$8.59M |
|
|
3
Biogen
BIIB
$19.4B
| $152M | 6.49% | 537,350 +55,317 | +11% | +$15.7M |
|
|
ALXN
4
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $97.4M | 4.15% | 795,905 +31,900 | +4% | +$3.9M |
|
|
AGN
5
DELISTED
Allergan plc
AGN
| $91.2M | 3.88% | 434,086 | – | – |
|
6
Incyte
INCY
$16.5B
| $88.3M | 3.76% | 880,461 | – | – |
|
7
Vertex Pharmaceuticals
VRTX
$100B
| $76.1M | 3.24% | 1,033,503 | – | – |
|
8
Merck
MRK
$210B
| $70.5M | 3.01% | 1,198,349 -48,048 | -4% | -$2.83M |
|
|
9
Regeneron Pharmaceuticals
REGN
$61.5B
| $68.9M | 2.93% | 187,666 +33,400 | +22% | +$12.3M |
|
10
Abbott
ABT
$231B
| $60.8M | 2.59% | 1,583,700 +205,100 | +15% | +$7.88M |
|
|
11
Johnson & Johnson
JNJ
$427B
| $51.1M | 2.18% | 443,212 +105,900 | +31% | +$12.2M |
|
12
BioMarin Pharmaceuticals
BMRN
$11.2B
| $47.4M | 2.02% | 572,645 -137,500 | -19% | -$11.4M |
|
13
Amgen
AMGN
$155B
| $47M | 2% | 321,640 | – | – |
|
14
Medtronic
MDT
$119B
| $44.4M | 1.89% | 623,030 | – | – |
|
15
Viatris
VTRS
$12.3B
| $43.3M | 1.85% | 1,135,552 | – | – |
|
|
SHPG
16
DELISTED
Shire pic
SHPG
| $39.4M | 1.68% | 231,413 | – | – |
|
|
17
UnitedHealth
UNH
$281B
| $39.4M | 1.68% | 245,920 -85,180 | -26% | -$13.6M |
|
18
Pfizer
PFE
$141B
| $37.2M | 1.59% | 1,146,689 | – | – |
|
|
19
Eli Lilly
LLY
$657B
| $36.3M | 1.55% | 493,100 -220,667 | -31% | -$16.2M |
|
20
Jazz Pharmaceuticals
JAZZ
$7.75B
| $36.1M | 1.54% | 331,411 | – | – |
|
21
Humana
HUM
$36.5B
| $33.6M | 1.43% | 164,800 | – | – |
|
22
CVS Health
CVS
$92.8B
| $32.5M | 1.38% | 411,891 | – | – |
|
23
Illumina
ILMN
$15.8B
| $31.6M | 1.34% | 246,560 | – | – |
|
24
Teva Pharmaceuticals
TEVA
$21.1B
| $28.6M | 1.22% | 788,958 | – | – |
|
|
MDCO
25
DELISTED
Medicines Co
MDCO
| $26.2M | 1.12% | 771,638 +207,200 | +37% | +$7.03M |
|